Factor XIa (FXIa) is a promising new target that may help address current unmet needs for thromboembolic diseases.1
Current treatments predominantly target factors within the common pathway that are essential for physiological hemostasis, introducing a potential bleeding risk.1
Watch the video to learn more about the role of FXIa in the coagulation cascade.
Bristol Myers Squibb and Johnson & Johnson are investigating the potential of factor XIa and what it could mean for thromboembolic diseases.
Reference
- Nopp S, Kraemmer D, Ay C. Factor XI inhibitors for prevention and treatment of venous thromboembolism: a review on the rationale and update on current evidence. Front Cardiovasc Med. 2022;9:903029. doi:10.3389/fcvm.2022.903029